跳至主要内容

Effect of Bromocriptine on Insulin Resistance in Patients with PCO

Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=52744#.VKIMVcCAM4

Introduction: Poly cystic ovary (PCO) is one of the most common endocrine disorders in women. All patients with PCO are at risk of insulin resistance, IFG and diabetes. Recently, bromocriptine is used in treatment of diabetes mellitus type II to improve insulin resistance. Objective: The aim of this study is the evaluation of bromocriptine on insulin resistance in PCO people. Patients and Methods: In this single-blind controlled clinical trial with placebo, 44 patients with PCO referring to endocrinology clinic were evaluated. Inclusion criteria were BMI > 25 kg/m2 and diagnosed PCO patients according to Rotterdam criteria and rule out other causes. Blood samples were obtained for FBS, Fasting Insulin, Prolactin, TSH and 17(OH)P. They divided two groups: Case group was given bromocriptine 2.5 mg daily and placebo was given to control group. Patients were treated for 8 days and in day 9th blood sample was obtained for FBS, Fasting insulin, HOMA-IR index. Mann-Whitney method is used for mean comparison. Results: Data analysis using showed in pre diabetes range, mean changes of FBS, insulin level and IR in Groups 1 and 2 had significant differences(P = 0.004), but no significant different was found in FBS < 100 mg/dl (P = 0.92). In group with BMI < 30 kg/m2, no significant differences were found in changes in FBS < insulin level and IR (P = 0.13, 0.13, and 0.11 respectively). In group with BMI ≥ 30 kg/m2, no significant differences were found in changes in insulin level and IR (P = 0.69, 0.089 respectively). Mean systolic blood pressure changes in Group 1 and 2 in FBS > 100 mg/dl with (P = 0.036) were significant, but no significant difference showed in mean change of diastolic blood pressure in FBS > 100 mg/dl (P = 0.99). In FBS < 100 mg/dl mean changes in systolic and diastolic blood pressures were not significant (P = 0.6). Age showed no difference changes in effect on treatment in Groups 1 and 2 (P = 0.1). Conclusion: Our study showed, even in the short-term consumption, bromocriptine reduced FBS and insulin levels and insulin resistance in PCO patients with pre-diabetes range.
Cite this paper
Shirinpour, Z. , Ghaderian, B. , Rashidi, H. , Aleali, A. and Payami, S. (2014) Effect of Bromocriptine on Insulin Resistance in Patients with PCO. Open Journal of Endocrine and Metabolic Diseases, 4, 253-257. doi: 10.4236/ojemd.2014.412026.
 

[1] Hull, M.G.R. (1987) Epidemiology of Infertility and Polycystic Ovarian Disease: Endocrinological and Demographic Studies. Gynecological Endocrinology, 1, 235-245. http://dx.doi.org/10.3109/ 09513598709023610
[2] Dunaif, A. (1997) Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implication for Pathogenesis. Endocrine Reviews, 18, 774-800.
[3] Naderi, T., Akbarzadeh, M., Dabbaghmanesh, M.H. and Tabatabaei, H.R. (2012) Prevalence of Various Phenotypes of Polycystic Ovarian Syndrome among High School Girls of Shiraz (2009). The Journal of Qazvin University of Medical Sciences, 15, 60-67. (In Persian)
[4] Shivaprasad, C. and Kalra, S. (2011) Bromocriptin in Type 2 Diabetes Mellitus. Indian Journal of Endocrinology and Metabolism, 15, S17-S24.
[5] Ehrmann, D.A., Liljenquist, D.R., Kasza, K., Azziz, R., Legro, R.S., Ghazzi, M.N., and for the PCOS/Troglitazone Study Group (2006) Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism, 91, 48-53. http://dx.doi.org/10.1210/jc.2005-1329
[6] Ovalle, F. and Azziz, R. (2002) Insulin Resistance, Polycystic Ovary Syndrome, and Type 2 Diabetes Mellitus. Fertility and Sterility, 77, 1095-1105. http://dx.doi.org/10.1016/S0015-0282(02)03111-4
[7] Petersen, K.F. and Shulman, G.I. (2006) Etiology of Insulin Resistance. The American Journal of Medicine, 119, S10-S16. http://dx.doi.org/10.1016/j.amjmed.2006.01.009
[8] Legro, R.S., Castracane, V.D. and Kauffman, R.P. (2004) Detecting Insulin Resistance in Polycystic Ovary Syndrome: Purposes and Pitfalls. Obstetrical & Gynecological Survey, 59, 141-154. http://dx.doi.org/10.1097/01.OGX.0000109523.25076.E2
[9] Defronzo, R.A. (2011) Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes. Diabetes Care, 34, 789-794. http://dx.doi.org/10.2337/dc11-0064
[10] Kok, P., Roelfsema, F., Frolich, M., Van Pelt, J., Stokkel, M.P., Meinders, A.E. and Pijl, H. (2006) Activation of Dopamine D2 Receptors Simultaneously Ameliorates Various Metabolic Features of Obese Women. American Journal of Physiology—Endocrinology and Metabolism, 291, E1038-E1043. http://dx.doi.org/10.1152/ajpendo.00567.2005
[11] Dos Santos Silva, C.M., Barbosa, F.R., Lima, G.A., Warszawski, L., Fontes, R., Domingues, R.C. and Gadelha, M.R. (2011) BMI and Metabolic Profile in Patients with Prolactinoma before and after Treatment with Dopamine Agonists. Obesity (Silver Spring), 19, 800-805. http://dx.doi.org/10.1038/oby.2010.150
[12] Davis, L.M., Michaelides, M., Cheskin, L.J., Moran, T.H., Aja, S., Watkins, P.A., et al. (2009) Bromocriptine Administration Reduces Hyperphagia and Adiposity and Differentially Affects Dopamine D2 Receptor and Transporter Binding in Leptin-Receptor-Deficient Zucker Rats and Rats with Diet-Induced Obesity. Neuroendocrinology, 89, 152-162. http://dx.doi.org/10.1159/000170586
[13] Lin, J., Lin, G.N., Pan, J.Q., Kuang, S.S., Huang, X., Rao, Z.L., et al. (2010) Studies of Bromocriptine on Insulin Resistance and Oxidative Stress in Rats with Polycystic Ovary Syndrome and Metabolic Syndrome. Clinical Medicine & Engineering, 12, 1-6.
[14] Bahceci, M., Tuzcu, A., Bahceci, S. and Tuzcu, S. (2003) Is Hyperprolactinemia Associated with Insulin Resistance in Non-Obese Patients with Polycystic Ovary Syndrome? Journal of Endocrinological Investigation, 26, 655-659.
[15] Pasquali, R., Casimirri, F., Venturoli, S., Paradisi, R., Mattioli, L., Capelli, M., Melchionda, N. and Labò, G. (1983) Insulin Resistance in Patients with Polycystic Ovaries: Its Relationship to Body Weight and Androgen Levels. Acta Endocrinologica (Copenhagen), 104, 110-116.
[16] Holt, R.I., Barnett, A.H. and Bailey, C.J. (2010) Bromocriptine: Old Drug, New Formulation and New Indication. Diabetes, Obesity and Metabolism, 12, 1048-1057. http://dx.doi.org/10.1111/j.1463-1326.2010.01304.x                                 eww141230lx
标签：

评论

发表评论

此博客中的热门博文

Does Immigration Promote the Investment of the Monopolistic Firm?

In the present paper, we examine the effect of increasing uncertainty of immigrants’ growth on the optimal timing of investment of a firm that has a monopolistic power over the labor market. It is revealed that when the uncertainty of immigrants’ growth is more than a threshold level, increasing uncertainty of immigrants’ growth accelerates the optimal timing of firms’ investment and enhances the economic growth, even if the uncertainty of immigrants’ growth is formulated by the geometric Brownian motion, which is in sharp contrast to the standard result that an increase in the uncertainty postpones the optimal timing. With an increase in the immigrants over the past ten years, workforces in the host countries have been growing significantly to the extent that the immigrants represent 70% of the increase in the workforce in Europe, and 47% in the United States as OECD indicates. In the present paper, we attempted to investigate the effect of increased uncertainty caused by the growi...
发表评论
阅读全文

Education Policy Implementation: A Mechanism for Enhancing Primary Education Development in Zanzibar

Education is one of the fundamental rights of individuals; therefore, the government of a country needs to develop and strengthen educational policy and quality as well as to ensure that everyone has equal access to basic education. The improvement of access and quality of education in the world is becoming as an essential factor in development, whereas the basic education (primary school), is acknowledged as a foundation of the higher educational development for every country. To fulfill this goal, governments introduce several policies and procedures; however, it requires some reforms and participation from the politician, policymakers, and other stakeholders to re-examine educational policy so that it can lead to multiplication and betterment of the reforms. Educational reforms actually focus on accountability. A positive educational development and reform is very challenging and needs more effort and strategy on how to use and utilize the resources effectively as such it can achie...
发表评论
阅读全文